Varespladib methyl is under clinical development by Ophirex and currently in Phase II for Poisoning. According to GlobalData, Phase II drugs for Poisoning have a 69% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Varespladib methyl’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Varespladib methyl overview

varespladib is under development for the treatment of snake poisoning.. The drug candidate is administered through oral and intravenous route. A-002 (Varespladib methyl) was under development for the treatment of acute coronary syndrome and coronary artery disease. The drug candidate is administered orally. Varespladib methyl is a prodrug that is rapidly metabolized to varespladib. It is able to potently inhibit the enzymes of the human secretory phospholipase groups IIa, V and X and play a pivotal role in atherosclerotic disease and inflammation. Secreted phospholipase A2 group X (sPLA2-X) is one of the most potent enzymes of the phospholipase A2 lipolytic enzyme superfamily. Its high catalytic activity toward phosphatidylcholine (PC), the major phospholipid of cell membranes and low-density lipoproteins (LDL), has implicated sPLA2-X in chronic inflammatory conditions.

It was also under development for the treatment Coronavirus Disease 2019 (COVID-19).

Ophirex overview

Ophirex, inc. (Ophirex) is a pharmaceutical company which is working to develop safe, effective, and accessible initial treatment for snakebite envenoming mostly in rural, impoverished areas. Ophirex is headquartered in Corte Madera, California, the US.

For a complete picture of Varespladib methyl’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.